Plasmalogen Precursors Reduce Membrane Cholesterol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical therapies for reducing cholesterol levels are limited, as they primarily involve inhibiting cholesterol synthesis with statins or blocking cholesterol absorption, with no drugs available to mobilize cholesterol out of membranes, leading to ineffective management of diseases associated with abnormal membrane cholesterol levels such as neurodegenerative disorders and cancers.
Innovation Solution
Development of novel 1-alkyl, 2-acyl glycerol derivatives that act as plasmalogen precursors, decreasing membrane free cholesterol levels by augmenting cholesterol esterification for transport from cell membranes, thereby treating or preventing diseases related to elevated membrane cholesterol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to inhibit cholesterol synthesis, then cholesterol levels are reduced, but membrane cholesterol cannot be effectively mobilized and transported out of membranes
Solution Approach 1:
The patent introduces plasmalogen precursors as intermediary compounds that facilitate cholesterol transport. These precursors convert to plasmalogens in the endoplasmic reticulum, which then act as mediators to extract and transport cholesterol from cell membranes to lipid droplets for storage or export, thereby resolving the limitation of statins that cannot mobilize membrane cholesterol
Solution Approach 2:
The invention segments the cholesterol management process into distinct phases: (1) synthesis inhibition by statins, (2) membrane cholesterol mobilization by plasmalogen precursors, and (3) cholesterol transport to lipid droplets. This segmentation allows each component to address specific aspects of cholesterol metabolism that cannot be handled by a single mechanism
2Quantity of substance
If ezetimibe is used to block cholesterol absorption, then gastrointestinal cholesterol absorption is reduced, but membrane cholesterol remains elevated and cannot be mobilized
Solution Approach 1:
Plasmalogen precursors serve as intermediary agents that bridge the gap between reduced cholesterol absorption and the need to clear existing membrane cholesterol. These compounds enable the mobilization and transport of cholesterol from membranes to storage sites, providing a reliable mechanism for disease management that complements absorption blocking
3Quantity of substance
If peroxisomal ether lipid biosynthesis is used to produce plasmalogens, then plasmalogen levels increase, but the pathway becomes less effective with ageing
Solution Approach 1:
The patent applies preliminary action by providing plasmalogen precursors that are converted to active plasmalogens in the endoplasmic reticulum before cholesterol transport occurs. This bypasses the age-declining peroxisomal pathway and ensures sufficient plasmalogen levels are achieved through an alternative, age-resistant biosynthetic route
Solution Approach 2:
The endoplasmic reticulum is utilized as an alternative intermediary site for plasmalogen synthesis, replacing the declining peroxisomal pathway. This intermediary location maintains effective plasmalogen production and function even in aged individuals
4Quantity of substance
If membrane cholesterol levels are elevated, then neurodegenerative diseases and cancers increase in prevalence, but current therapies cannot effectively reduce membrane cholesterol
Solution Approach 1:
Plasmalogen precursors and the resulting plasmalogens act as intermediary molecules that facilitate the extraction and transport of cholesterol from cell membranes. This intermediary mechanism directly addresses elevated membrane cholesterol levels associated with neurodegenerative diseases and cancers, providing a therapeutic approach that current medications cannot achieve
Solution Approach 2:
The invention implements extraction by using plasmalogens to remove cholesterol from cell membranes and transport it to lipid droplets. This extraction process directly reduces membrane cholesterol levels that are pathologically elevated in various diseases, addressing the harmful effect of membrane cholesterol accumulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce membrane cholesterol levels, decrease amyloid secretion, and increase plasmalogen levels, providing therapeutic benefits for neurodegenerative diseases, cancers, and vascular diseases by bypassing peroxisomal ether lipid biosynthesis pathways.
Implementation Method 1
the sn-3 substituent is cleaved by lipases and the resulting 1-alkyl, 2-acyl glycerol or 1-alkenyl, 2-acyl glycerol is then converted to plasmalogens
Implementation Method 2
the resulting 1-alkyl, 2-acyl glycerol or 1-alkenyl, 2-acyl glycerol is then converted to plasmalogens in the endoplasmic reticulum
Implementation Method 3
decrease membrane free cholesterol levels and augment cholesterol esterification for transport from cell membranes
Data Source
Figure 1~2
Figure 3A~3B
Figure 4A~4B
AI summary
Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).